Ranitidine (Page 2 of 5)

2. Effects on Other Gastrointestinal Secretions

Pepsin

Oral ranitidine does not affect pepsin secretion. Total pepsin output is reduced in proportion to the decrease in volume of gastric juice.

Intrinsic Factor

Oral ranitidine has no significant effect on pentagastrin-stimulated intrinsic factor secretion.

Serum Gastrin

Ranitidine has little or no effect on fasting or postprandial serum gastrin.

Other Pharmacologic Actions

a.
Gastric bacterial flora—increase in nitrate-reducing organisms, significance not known.
b.
Prolactin levels—no effect in recommended oral or intravenous (IV) dosage, but small, transient, dose-related increases in serum prolactin have been reported after IV bolus injections of 100 mg or more.
c.
Other pituitary hormones—no effect on serum gonadotropins, TSH, or GH. Possible impairment of vasopressin release.
d.
No change in cortisol, aldosterone, androgen, or estrogen levels.
e.
No antiandrogenic action.
f.
No effect on count, motility, or morphology of sperm.

Pediatrics

Oral doses of 6 to 10 mg/kg per day in two or three divided doses maintain gastric pH>4 throughout most of the dosing interval.

Clinical Trials

Active Duodenal Ulcer

In a multicenter, double-blind, controlled, US study of endoscopically diagnosed duodenal ulcers, earlier healing was seen in the patients treated with ranitidine as shown in Table 3.

Table 3: Duodenal Ulcer Patient Healing Rates
Ranitidine * Placebo *
Number Entered Healed/Evaluable Number Entered Healed/Evaluable
*
All patients were permitted antacids as needed for relief of pain.
<0.0001. P
Outpatients
Week 2 69/182 31/164
(38%) (19%)
195 188
Week 4 137/187 76/168
(73%) (45%)

In these studies, patients treated with ranitidine reported a reduction in both daytime and nocturnal pain, and they also consumed less antacid than the placebo-treated patients.

Table 4: Mean Daily Doses of Antacid
Ulcer Healed Ulcer Not Healed
Ranitidine 0.06 0.71
Placebo 0.71 1.43

Foreign studies have shown that patients heal equally well with 150 mg twice daily and 300 mg at bedtime (85% versus 84%, respectively) during a usual 4-week course of therapy. If patients require extended therapy of 8 weeks, the healing rate may be higher for 150 mg twice daily as compared to 300 mg at bedtime (92% versus 87%, respectively).

Studies have been limited to short-term treatment of acute duodenal ulcer. Patients whose ulcers healed during therapy had recurrences of ulcers at the usual rates.

Maintenance Therapy in Duodenal Ulcer

Ranitidine has been found to be effective as maintenance therapy for patients following healing of acute duodenal ulcers. In two independent, double-blind, multicenter, controlled trials, the number of duodenal ulcers observed was significantly less in patients treated with ranitidine (150 mg at bedtime) than in patients treated with placebo over a 12-month period.

Table 5: Duodenal Ulcer Prevalence
Double-blind, Multicenter, Placebo-Controlled Trials
Multicenter Trial Drug Duodenal Ulcer Prevalence No. of Patients
% = Life table estimate. RAN — ranitidine. PLC = placebo.
*
= P<0.05 (ranitidine versus comparator).
0-4 Months 0-8 Months 0-12 Months
RAN 20% * 24% * 35% * 138
USA PLC 44% 54% 59% 139
RAN 12% * 21% * 28% * 174
Foreign PLC 56% 64% 68% 165

As with other H2-antagonists, the factors responsible for the significant reduction in the prevalence of duodenal ulcers include prevention of recurrence of ulcers, more rapid healing of ulcers that may occur during maintenance therapy, or both.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.